参考文献/References:
[1] 倪嘉缵, 陈平, 刘琼, 等. 阿尔茨海默病的防治策略研究进展[J]. 深圳大学学报理工版, 2013, 30(4): 331-348.
Ni Jiazuan, Chen Ping, Liu Qiong, et al. Advance reseach on strategies for the prevention of Alzheimer’s disease[J]. Journal of Shenzhen University Science and Engineering, 2013, 30(4): 331-348.(in Chinese)
[2] 李冰石, 薛山, 宋国丽. 纳米粒子对amyloid-β聚集的影响的研究进展[J]. 深圳大学学报理工版, 2015, 32(6): 601-609.
Li Bingshi, Xue Shan, Song Guoli. Review of the influence of nanoparticles on aggregation of amyloid-β[J]. Journal of Shenzhen University Science and Engineering, 2015, 32(6): 601-609.(in Chinese)
[3] Wu Haiqiang, Zhang Fang, Williamson N, et al. Effects of secondary metabolite extract from Phomopsisocculta on beta-amyloid aggregation[J]. PLOS One, 2014, 9(10): e109438.
[4] Citron M. Alzheimer’s disease: strategies for disease modification[J]. Nature Reviews Drug Discovery, 2010, 9(5): 387-398.
[5] Fu Ziao, Aucoin D, Ahmed M, et al. Capping of Aβ42 oligomers by small molecule inhibitors[J]. Biochemistry, 2014, 53(50): 7893-7903.
[6] Stefani M. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer’s disease and other diseases with amyloid deposits[J]. Progress in Neurobiology, 2012, 99(3): 226-245.
[7] Ehrnhoefer D E, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers[J]. Nature Structural & Molecular Biology, 2008, 15(6): 558-566.
[8] Mastrangelo I A, Ahmed M, Sato T, et al. High-resolution atomic force microscopy of soluble Aβ42 oligomers[J]. Journal of Molecular Biology, 2006, 358(1): 106-119.
[9] Kayed R, Head E, Thompson J L, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis[J]. Science, 2003, 300(5618): 486-489.
[10] Kelly B L, Ferreira A. Beta-amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons[J]. Journal of Biological Chemistry, 2006, 281(38): 28079-28089.
[11] Caesar I, Jonson M, Nilsson K P R, et al. Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila [J]. PLOS One, 2012, 7(2): e31424.
[12] Cui Lili, Zhang Yuan, Cao Hao, et al. Ferulic acid inhibits the transition of amyloid-beta 42 monomers to oligomers but accelerates the transition from oligomers to fibrils[J]. Journal of Alzheimer’s Disease, 2013, 37(1): 19-28.
[13] Ladiwala A R A, Lin J C, Bale S S, et al. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers[J]. Journal of Biological Chemistry, 2010, 285(31): 24228-24237.
[14] Zheng Qichang, Chen Guodong, Kong Mingzhu, et al. Nodulisporisteriods A and B, the first 3,4-seco-4-methyl-progesteroids from Nodulisporium sp.[J]. Steroids, 2013, 78(9): 896-901.
[15] Keskitalo S, Farkas M, Hanenberg M, et al. Reciprocal modulation of Aβ42 aggregation by copper and homocysteine[J]. Frontiers in Aging Neuroscience, 2014, 6: 237.
[16] Bhattacharya A, Prajapati R, Chatterjee S, et al. Concentration-dependent reversible self-oligomerization of serum albumins through intermolecular β-sheet formation[J]. Langmuir, 2014, 30(49): 14894-14904.
[17] Han Sunho, Chang Yujin, Jung Eunsun, et al. Effective screen for amyloid beta aggregation inhibitor using amyloid beta-conjugated gold nanoparticles[J]. Journal of Nanomedicine, 2011, 6: 1-12.
[18] Fowler S B, Poon S, Muff R, et al. Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin[J]. Proceedings of the National Academy of Sciences, 2005, 102(29): 10105-10110.
[19] Takai E, Uda K, Yoshida T, et al. Cysteine inhibits the fibrillisation and cytotoxicity of amyloid-beta 40 and 42: implications for the contribution of the thiophilic interaction[J]. Physical Chemistry Chemical Physics, 2014, 16(8): 3566-3572.
[20] Poduslo J F, Howell K G, Olson N C, et al. Alzheimer’s disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillaraggregates and late stage fibrils[J]. Biochemistry, 2012, 51(19): 3993-4003.
[21] Poduslo J F, Howell K G. Unique molecular signatures of Alzheimer’s disease amyloid β peptide mutations and deletion during aggregate/oligomer/fibril formation[J]. Journal of Neuroscience Research, 2015, 93(3): 410-423.
[22] Jan A, Hartley D M, Lashuel H A. Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer’s disease research[J]. Nature Protocols, 2010, 5(6): 1186-1209.
[23] Necula M, Kayed R, Milton S, et al. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillizationpathways are independent and distinct[J]. Journal of Biological Chemistry, 2007, 282(14): 10311-10324.